Jasper’s Development Pipeline
Jasper maintains full worldwide rights to develop and commercialize briquilimab in all indications
Briquilimab
Chronic Spontaneous Urticaria
Chronic Inducible Urticaria
Low to Intermediate Risk MDS
SCID
- Fanconi Anemia
- Sickle Cell Disease
- Chronic Granulomatous Disease
- GATA2 MDS
MDS: Myelodysplastic Syndrome
SCID: Severe Combined Immunodeficiency
GATA2 MDS: MDS with germline GATA2 mutations
EXPANDED ACCESS
Jasper is a clinical stage biotechnology company focused on the development of novel curative therapies by focusing on the biology of the hematopoietic stem cell. Jasper’s lead program, Briquilimab, is an investigational therapy currently being studied in multiple clinical trials for serious and life-threatening conditions. Participation in a clinical trial of Briquilimab is the best way to access Briquilimab investigational therapy. Jasper does not currently provide access to our investigational therapies under Expanded Access.